HC Wainwright Weighs in on Biora Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:BIOR)

Biora Therapeutics, Inc. (NASDAQ:BIORGet Rating) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Biora Therapeutics in a research note issued on Tuesday, January 10th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($3.60) for the year. The consensus estimate for Biora Therapeutics’ current full-year earnings is ($6.50) per share.

Biora Therapeutics (NASDAQ:BIORGet Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($50.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($37.50) by ($12.50). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.10 million.

Biora Therapeutics Stock Performance

Shares of BIOR stock opened at $5.30 on Thursday. The stock’s 50 day simple moving average is $112.32 and its 200 day simple moving average is $300.67. Biora Therapeutics has a twelve month low of $1.95 and a twelve month high of $52.75. The company has a market capitalization of $47.31 million, a price-to-earnings ratio of -0.30 and a beta of 1.04.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in Biora Therapeutics in the 3rd quarter worth approximately $27,000. Commonwealth Equity Services LLC bought a new position in Biora Therapeutics in the 3rd quarter worth approximately $63,000. State Street Corp bought a new position in Biora Therapeutics in the 3rd quarter worth approximately $213,000. BlackRock Inc. bought a new position in Biora Therapeutics in the 3rd quarter worth approximately $789,000. Finally, Vanguard Group Inc. bought a new position in Biora Therapeutics in the 3rd quarter worth approximately $2,860,000. 54.13% of the stock is owned by institutional investors.

About Biora Therapeutics

(Get Rating)

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake.

Read More

Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.